Business Context and Reporting Period
Company: Quantum X Labs Inc. (QXL)
Filing Type: Form 8-K (Current Report)
Date of Report: September 15, 2026
Reporting Period: Single event date (September 15, 2026)
Business Context: The filing discloses a significant corporate governance and strategic advisory appointment rather than routine financial reporting.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue figures, profit data, cash flow metrics, debt levels, or liquidity ratios. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the appointment of a high-profile executive to the Scientific Advisory Board:
- Appointment: Yossi Cohen appointed as President of the Scientific Advisory Board.
- Background: Former Director of the Mossad (2016–2021) and former National Security Advisor of Israel (2013–2016).
- Recent Role: Strategic Advisor to SoftBank (appointed August 2026) and previously led SoftBank Vision Fund 2 activities in Israel.
Guidance, Outlook, and Risks
Management Commentary: The filing highlights Mr. Cohen's expertise at the intersection of national security and global technology investments, suggesting a strategic alignment with the Company's focus areas.
Guidance/Outlook: No financial guidance or forward-looking projections were included in this filing.
Risks/Contingencies: No specific risks or contingencies were disclosed in this report. The filing notes that the information furnished under Item 7.01 is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on Mr. Cohen's compensation or specific strategic mandates.
- Confirm if this appointment triggers any changes to the Company's board composition or voting rights.
- Review recent SoftBank announcements to understand the context of Mr. Cohen's transition from SoftBank to Quantum X Labs.
- Check subsequent filings (e.g., 10-Q or 10-K) for any financial impact or strategic initiatives resulting from this appointment.